| 0.24 -0.02 (-7.73%) | 03-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.42 | 1-year : | 0.52 |
| Resists | First : | 0.36 | Second : | 0.44 |
| Pivot price | 0.28 |
|||
| Supports | First : | 0.23 | Second : | 0.19 |
| MAs | MA(5) : | 0.26 |
MA(20) : | 0.29 |
| MA(100) : | 0.47 |
MA(250) : | 0.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.4 |
D(3) : | 15.4 |
| RSI | RSI(14): 36.5 |
|||
| 52-week | High : | 3.18 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ISPC ] has closed above bottom band by 12.2%. Bollinger Bands are 54.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 87 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.26 - 0.26 | 0.26 - 0.26 |
| Low: | 0.23 - 0.24 | 0.24 - 0.24 |
| Close: | 0.24 - 0.24 | 0.24 - 0.24 |
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
Tue, 03 Mar 2026
ISPC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Fri, 27 Feb 2026
iSpecimen (ISPC) Pops on Nano Antibody News: Can The Rally Last? - AD HOC NEWS
Wed, 25 Feb 2026
ISPC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wed, 25 Feb 2026
ISPC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Mon, 23 Feb 2026
Director Siyun Yang leaves iSpecimen (NASDAQ: ISPC) board role - Stock Titan
Fri, 06 Feb 2026
iSpecimen Achieves Rapid Procurement Milestone for Influenza Research - TMX Newsfile
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 9.73e+006 (%) |
| Held by Institutions | 0.6 (%) |
| Shares Short | 1,140 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.187e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 655.1 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 3.35e+006 % |
| Gross Profit (p.s.) | -52.18 |
| Sales Per Share | -160.98 |
| EBITDA (p.s.) | 392685 |
| Qtrly Earnings Growth | -7.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.42 |
| Dividend | 0 |
| Forward Dividend | 314310 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|